Key Highlights

  • Johnson & Johnson shares are trading at $259.45 in Thursday's session, down 2.00%.
  • No company-specific negative has been identified; the move looks like profit-taking in a stock that has climbed roughly 43% over the past year.
  • The company released a global women's eye health survey on Thursday, which is not a financial disclosure.
  • Investors are looking ahead to third-quarter Earnings on October 13, with consensus calling for about $25.3 billion in revenue.

Profit-Taking Hits a Stock Sitting Near Record Highs

Johnson & Johnson (NYSE:JNJ) is pulling back in Thursday's session, giving up ground after a run that lifted the shares roughly 43% over the past year to levels near record highs. The stock is trading around $259, down 2.00%, against a 52-week high of $281.07.

No company-specific negative has been identified. The decline looks more like valuation-driven profit-taking in a softer healthcare group, with the broader market also slightly lower as Treasury yields stay near multi-decade highs.

A Women's Eye Health Survey Is the Only Company Headline

The company's one announcement of the day was a global survey of 6,000 women across six countries on vision changes during menopause. It found that only 40% connect eye changes with the menopause transition and that just 18% have booked an annual eye exam.

The release is awareness-focused and carries no financial guidance, so it does not explain the share price move.

Oncology and Immunology Data Built the Recent Momentum

Recent strength has come from data for Carvykti, Tremfya and Tecvayli, along with signs that the company is offsetting Revenue erosion from Stelara biosimilars. The rally has pushed the stock to a forward earnings multiple of about 21 times, which some commentators view as a premium for a company of its size.

Mixed Analyst Views Frame the October 13 Earnings Test

Analyst opinion is split. One brokerage recently raised its price target to $285 while keeping a Neutral rating, and another holds Neutral with a $278 target. Investors now look to third-quarter results on October 13, with consensus calling for about $25.3 billion in revenue.